



CLIENT CODE: C000138382 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.itpl@srl.in

PATIENT ID: **PATIENT NAME: K V MOHANDASS** KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS,EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	14.5		13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT	5.5		4.5 - 5.5	mil/μL
WHITE BLOOD CELL (WBC) COUNT	7.50		4.0 - 10.0	thou/µL
PLATELET COUNT	447	High	150 - 410	thou/µL
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	43.9		40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV)	80.0	Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.3	Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	33.1		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.6	High	11.6 - 14.0	%
MENTZER INDEX	14.5			
MEAN PLATELET VOLUME (MPV)	6.8		6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	60		40 - 80	%
LYMPHOCYTES	29		20 - 40	%
MONOCYTES	5		2 - 10	%
EOSINOPHILS	5		1 - 6	%
BASOPHILS	1		0 - 2	%
ABSOLUTE NEUTROPHIL COUNT	4.50		2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT	2.18		1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT	0.38		0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT	0.38		0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0.08		0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.1			

MORPHOLOGY

RBC NORMOCYTIC NORMOCHROMIC

WBC NORMAL IN COUNT, MORPHOLOGY AND DISTRIBUTION

PLATELETS INCREASED IN COUNT

NO HEMOPARASITES SEEN









mm at 1 hr

CLIENT CODE: C000138382 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.itpl@srl.in

PATIENT ID: **PATIENT NAME: K V MOHANDASS** KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 27/02/2023 17:11 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final Results Biological Reference Interval** Units

IMPRESSION NORMOCYTIC NORMOCHROMIC BLOOD PICTURE WITH

THROMBOCYTOSIS

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE

BLOOD

E.S.R 80 0 - 14

METHOD: MODIFIED WESTERGREN

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 111 High 74 - 99 mg/dL

METHOD: SPECTROPHOTOMETRY HEXOKINASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C 5.3 Non-diabetic: < 5.7 %

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5ADA Target: 7.0 Action suggested: > 8.0

METHOD: PARTICLE-ENHANCED TURBIDIMETRIC INHIBITION IMMUNOASSAY(PETINIA)

105.4 ESTIMATED AVERAGE GLUCOSE(EAG) < 116.0 mg/dL

METHOD: PARTICLE-ENHANCED TURBIDIMETRIC INHIBITION IMMUNOASSAY(PETINIA)

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 142 High 70 - 139 mg/dL

METHOD: SPECTROPHOTOMETRY HEXOKINASE

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL 231 High < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High

TRIGLYCERIDES **High** < 150 Normal 225 mg/dL

150 - 199 Borderline High

200 - 499 High

>/=500 Very High

METHOD: LIPOPROTEIN LIPASE (LPL), GLYCEROL KINASE (GK) HDL CHOLESTEROL 27

METHOD: SPECTROPHOTOMETRY, CHOLESTEROL OXIDASE ESTERASE PEROXIDASE

Low < 40 Low mg/dL >/=60 High

METHOD: DIRECT HDL, PEGME

CHOLESTEROL LDL 159 High < 100 Optimal mg/dL

100 - 129

Near optimal/ above optimal

130 - 159 Borderline High 160 - 189 High

>/= 190 Very High









CLIENT CODE: C000138382 **CLIENT'S NAME AND ADDRESS:** ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

DRAWN: 25/02/2023 08:09

DELHI INDIA

8800465156

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

27/02/2023 17:11

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.itpl@srl.in

REPORTED:

PATIENT ID: **PATIENT NAME: K V MOHANDASS** KVMOM09068075

0075WB00182 ACCESSION NO: AGE: 42 Years SEX: Male ABHA NO:

RECEIVED: 25/02/2023 08:11

CLIENT PATIENT ID: REFERRING DOCTOR: SELF

Test Report Status <u>Final</u>	Results	Results Biological Reference Interval		
METHOD: DIRECT ENZYME CLEARANCE NON HDL CHOLESTEROL	204	Hiah	Desirable: Less than 130	mg/dL
			Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	9, a.
METHOD : CALCULATED PARAMETER				
VERY LOW DENSITY LIPOPROTEIN	45.0	High	= 30.0</td <td>mg/dL</td>	mg/dL
CHOL/HDL RATIO	8.6	High	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	5.9	High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk









CLIENT CODE: C000138382
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS

PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations

- 2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.
- 3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL
- 4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.
- 5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category						
Extreme risk group	A.CAD with > 1 feature of high risk group	A.CAD with > 1 feature of high risk group				
	B. CAD with > 1 feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C				
	< or = 50 mg/dl or polyvascular disease					
Very High Risk	1. Established ASCVD 2. Diabetes with 2 i	major risk factors or evidence of end organ damage 3.				
	Familial Homozygous Hypercholesterolemi					
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end					
	organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.					
	Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid					
	plaque					
Moderate Risk	2 major ASCVD risk factors					
Low Risk	0-1 major ASCVD risk factors					
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors						
1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females		3. Current Cigarette smoking or tobacco use				
2. Family history of premature ASCVD		4. High blood pressure				
5. Low HDL						

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.











CLIENT CODE: C000138382

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	$\langle OR = 30 \rangle$	$\langle OR = 60 \rangle$		
Extreme Risk Group	<OR = 30	< OR = 60	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

^{*}After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.60		0.2 - 1.0	mg/dL				
METHOD: SPECTROPHOTOMETRY								
BILIRUBIN, DIRECT	0.10		0.0 - 0.2	mg/dL				
METHOD: SPECTROPHOTOMETRY								
BILIRUBIN, INDIRECT	0.50		0.1 - 1.0	mg/dL				
METHOD: CALCULATED PARAMETER								
TOTAL PROTEIN	7.6		6.4 - 8.2	g/dL				
METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET								
ALBUMIN	3.8		3.4 - 5.0	g/dL				
METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)								
GLOBULIN	3.8		2.0 - 4.1	g/dL				
METHOD: CALCULATED PARAMETER								
ALBUMIN/GLOBULIN RATIO	1.0		1.0 - 2.1	RATIO				
METHOD: CALCULATED PARAMETER								
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	25		15 - 37	U/L				
METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -5-PHOSPHATE								
ALANINE AMINOTRANSFERASE (ALT/SGPT)	48 H	High	< 45.0	U/L				
METHOD: SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -5-PHOSPI	IATE							
ALKALINE PHOSPHATASE	100		30 - 120	U/L				
METHOD: SPECTROPHOTOMETRY								
GAMMA GLUTAMYL TRANSFERASE (GGT)	29		15 - 85	U/L				
METHOD : SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITRONILIDE								
LACTATE DEHYDROGENASE	156		100 - 190	U/L				
METHOD: SPECTROPHOTOMETRY								









CLIENT CODE: C000138382

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030
DELHI INDIA

8800465156

SRL Ltd 7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

BLOOD UREA NITROGEN (BUN), SERUM BLOOD UREA NITROGEN 12 6 - 20 mg/dL CREATININE, SERUM CREATININE 0.97 0.90 - 1.30 mg/dL METHOD: SPECTROPHOTOMETRIC, JAFFE'S KINETICS BUN/CREAT RATIO 12.37 5.00 - 15.00 URIC ACID, SERUM URIC ACID, SERUM URIC ACID 6.8 3.5 - 7.2 mg/dL METHOD: SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN SERUM ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units						
BLOOD UREA NITROGEN CREATININE, SERUM CREATININE CREATINICE CREATININE CREATININE CREATINICE CREATININE CREATINICE CREATININE CREATINICE CREATININE CREATINICE CR	BLOOD UREA NITROGEN (BUN), SERUM									
CREATININE, SERUM CREATININE O.97 O.90 - 1.30 mg/dL METHOD: SPECTROPHOTOMETRIC, JAFFE'S KINETICS BUN/CREAT RATIO BUN/CREAT RATIO BUN/CREAT RATIO ORDINATION BUN/CREAT RATIO ORDINATION URIC ACID, SERUM URIC ACID METHOD: SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN SERUM METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN SERUM METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN SERUM METHOD: SPECTROPHOTOMETRY BROMOCRESOL GREEN (BCG)	•		6 - 20	ma/dL						
CREATININE METHOD: SPECTROPHOTOMETRIC, JAFFE'S KINETICS BUN/CREAT RATIO BUN/CREAT RATIO 12.37 5.00 - 15.00 URIC ACID, SERUM URIC ACID METHOD: SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN, SERUM METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM METHOD: SPECTROPHOTOMETRY BROMOCRESOL GREEN (BCG)	CREATININE, SERUM			3,						
METHOD: SPECTROPHOTOMETRIC, JAFFE'S KINETICS BUN/CREAT RATIO 12.37 5.00 - 15.00 URIC ACID, SERUM URIC ACID METHOD: SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN, SERUM METHOD: SPECTROPHOTOMETRY BROMOCRESOL GREEN (BCG)	•	0.97	0.90 - 1.30	mg/dL						
BUN/CREAT RATIO URIC ACID, SERUM URIC ACID METHOD: SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN, SERUM METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN SERUM METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	METHOD : SPECTROPHOTOMETRIC, JAFFE	IETICS		3, -						
URIC ACID, SERUM URIC ACID 6.8 3.5 - 7.2 mg/dL METHOD : SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.6 6.4 - 8.2 g/dL METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD : SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	BUN/CREAT RATIO									
URIC ACID METHOD: SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN SERUM ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	BUN/CREAT RATIO	12.37	5.00 - 15.00							
METHOD: SPECTROPHOTOMETRY TOTAL PROTEIN, SERUM TOTAL PROTEIN 7.6 6.4 - 8.2 g/dL METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	URIC ACID, SERUM									
TOTAL PROTEIN, SERUM TOTAL PROTEIN ALBUMIN, SERUM ALBUMIN METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN 3.8 ALBUMIN 3.8 ALBUMIN 3.4 - 5.0 METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	URIC ACID	6.8	3.5 - 7.2	mg/dL						
TOTAL PROTEIN 7.6 6.4 - 8.2 g/dL METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	METHOD: SPECTROPHOTOMETRY									
METHOD : SPECTROPHOTOMETRY, MODIFIED BIURET ALBUMIN, SERUM ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD : SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	TOTAL PROTEIN, SERUM									
ALBUMIN, SERUM ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	TOTAL PROTEIN	7.6	6.4 - 8.2	g/dL						
ALBUMIN 3.8 3.4 - 5.0 g/dL METHOD: SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	METHOD: SPECTROPHOTOMETRY, MODIF	IURET								
METHOD : SPECTROPHOTOMETRIC - BROMOCRESOL GREEN (BCG)	ALBUMIN, SERUM									
	ALBUMIN	3.8	3.4 - 5.0	g/dL						
GLOBULIN	METHOD: SPECTROPHOTOMETRIC - BRON	ESOL GREEN (BCG)								
	GLOBULIN									
GLOBULIN 3.8 2.0 - 4.1 g/dL	GLOBULIN	3.8	2.0 - 4.1	g/dL						
METHOD: CALCULATED PARAMETER	METHOD: CALCULATED PARAMETER									
ELECTROLYTES (NA/K/CL), SERUM	ELECTROLYTES (NA/K/CL), S	M								
SODIUM, SERUM 139.2 137 - 145 mmol/	SODIUM, SERUM	139.2	137 - 145	mmol/L						
POTASSIUM, SERUM 4.71 3.6 - 5.0 mmol/	POTASSIUM, SERUM	4.71	3.6 - 5.0	mmol/L						
CHLORIDE, SERUM 106.9 98 - 107 mmol/	CHLORIDE, SERUM	106.9	98 - 107	mmol/L						









CLIENT CODE: C000138382 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI

NEW DELHI 110030 DELHI INDIA 8800465156

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.itpl@srl.in

PATIENT ID: **PATIENT NAME: K V MOHANDASS** KVMOM09068075

0075WB00182 ACCESSION NO: AGE: 42 Years SEX: Male ABHA NO:

RECEIVED: 25/02/2023 08:11 DRAWN: 25/02/2023 08:09 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results **Biological Reference Interval** Units

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW	
APPEARANCE	CLEAR	
CHEMICAL EXAMINATION, URINE		
PH	6.0	4.7 - 7.5
SPECIFIC GRAVITY	1.020	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED









CLIENT CODE: C000138382

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 1100220

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>		Results	Biological Reference	Interval Units
MICROSCOPIC EXAM	INATION, URINE			
RED BLOOD CELLS		NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)		2-3	0-5	/HPF
EPITHELIAL CELLS		1-2	0-5	/HPF
CASTS		NOT DETECTED		
CRYSTALS		NOT DETECTED		
BACTERIA		NOT DETECTED	NOT DETECTED	
YEAST		NOT DETECTED	NOT DETECTED	









CLIENT CODE: C000138382
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
	diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

THYROID PANEL, SERUM

T3 131.0 80.0 - 200.0 ng/dL T4 10.70 5.10 - 14.10 μ g/dL TSH (ULTRASENSITIVE) 0.999 0.270 - 4.200 μ IU/mL









CLIENT CODE: C000138382
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS

PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PHYSICAL EXAMINATION, STOOL

COLOUR SAMPLE NOT RECEIVED
CONSISTENCY SAMPLE NOT RECEIVED

MUCUS SAMPLE NOT RECEIVED NOT DETECTED

VISIBLE BLOOD SAMPLE NOT RECEIVED ABSENT









CLIENT CODE: C000138382

CLIENT'S NAME AND ADDRESS:
ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULI
SOUTH WEST DELHI
NEW DELHI 110030
DELHI INDIA

8800465156

SRL Ltd 7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>		Results	Biological Reference Interva	al Units
ADULT PARASITE		SAMPLE NOT RECEIVED		
CHEMICAL EXAMINA	TION,STOOL			
STOOL PH		SAMPLE NOT RECEIVED		
OCCULT BLOOD		SAMPLE NOT RECEIVED	NOT DETECTED	
MICROSCOPIC EXAM	INATION,STOOL			
PUS CELLS		SAMPLE NOT RECEIVED		/hpf
RED BLOOD CELLS		SAMPLE NOT RECEIVED	NOT DETECTED	/HPF
CYSTS		SAMPLE NOT RECEIVED	NOT DETECTED	
OVA		SAMPLE NOT RECEIVED		
LARVAE		SAMPLE NOT RECEIVED	NOT DETECTED	
TROPHOZOITES		SAMPLE NOT RECEIVED	NOT DETECTED	
REMARK		SAMPLE NOT RECEIVED		









CLIENT CODE: C000138382
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 5KL LTG 7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS

PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as
	ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS:

- Stool Culture: This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- 2. <u>Fecal Calprotectin</u>: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- 4. <u>Clostridium Difficile Toxin Assay</u>: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. <u>Biofire (Film Array) GI PANEL</u>: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test,(Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus ,parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.









CLIENT CODE: C000138382
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

6. Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B
RH TYPE POSITIVE

XRAY-CHEST

»» BOTH THE LUNG FIELDS ARE CLEAR

»» BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR

»» BOTH THE HILA ARE NORMAL

»» CARDIAC AND AORTIC SHADOWS APPEAR NORMAL

»» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL

»» VISUALIZED BONY THORAX IS NORMAL

IMPRESSION NORMAL

METHOD: MICROSCOPIC EXAMINATION

ECG

ECG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY

RELEVANT PAST HISTORY

RELEVANT PERSONAL HISTORY

RELEVANT FAMILY HISTORY

NOT SIGNIFICANT

NOT SIGNIFICANT

NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.72 mts
WEIGHT IN KGS. 83.9 Kgs

BMI 28 BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight

18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL
PHYSICAL ATTITUDE NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS HEALTHY









CLIENT CODE: C000138382
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156 SRL Ltd

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS

PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

BUILT / SKELETAL FRAMEWORK AVERAGE
FACIAL APPEARANCE NORMAL
SKIN NORMAL
UPPER LIMB NORMAL
TEMPERATURE NORMAL

PULSE REGULAR, ALL PERIPHERAL PULSES WELL FELT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

BP 110/70 mm/Hg

PERICARDIUM NORMAL APEX BEAT NORMAL

HEART SOUNDS S1, S2 HEARD NORMALLY

BASIC EYE EXAMINATION

DISTANT VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT
DISTANT VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT
NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT
NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT

COLOUR VISION NORMAL

BASIC DENTAL EXAMINATION

TEETH CARIES
GUMS HEALTHY

SUMMARY

RELEVANT HISTORY

RELEVANT GP EXAMINATION FINDINGS

NOT SIGNIFICANT

NOT SIGNIFICANT

NOT SIGNIFICANT

DYSLIPEDIMIA

ADVICE:-

TAB ROSUVAS 10 MG 0-0-1 X 3 MONTHS TO REPEAT LIPID PROFILE AFTER 3 MONTHS

RELEVANT NON PATHOLOGY DIAGNOSTICS NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS NONE

FITNESS STATUS

FITNESS STATUS FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)









CLIENT CODE: C000138382 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.itpl@srl.in

PATIENT ID: **PATIENT NAME: K V MOHANDASS** KVMOM09068075

0075WB00182 AGE: 42 Years ACCESSION NO: SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 27/02/2023 17:11 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final Results Biological Reference Interval** Units

Comments

*NOTE: NON PATHOLOGY TESTS ARE REVIEWED BY Consultant Physician: Dr.RITESH RAJ MBBS,CCEBDM

Radiologist: Dr.THILAK BABU Dental Doctor: Dr Ashish sinha BDS,

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading

to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION**:Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol sulfonylureas,tolbutamide, and other oral hypoglycemic agents.









CLIENT CODE: C000138382 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.itpl@srl.in

PATIENT ID: **PATIENT NAME: K V MOHANDASS** KVMOM09068075

0075WB00182 AGE: 42 Years SEX: Male ACCESSION NO: ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 27/02/2023 17:11 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final Results Biological Reference Interval** Units

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin Treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget''''''s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson''''''s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstrom''''''s disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing

enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:
• Blockage in the urinary tract

Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)

· Muscle problems, such as breakdown of muscle fibers

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)









CLIENT CODE: C000138382 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030 DELHI INDIA** 8800465156

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email: wellness.itpl@srl.in

PATIENT ID: **PATIENT NAME: K V MOHANDASS** KVMOM09068075

0075WB00182 AGE: 42 Years ACCESSION NO: SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 27/02/2023 17:11 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final Results Biological Reference Interval** Units

Lower than normal level may be due to:

Myasthenia Gravis

Muscular dystrophy

URIC ACID, ŚERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and globulin

syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history as well as the comprehensiveness of the diagnostic panel which has been requested for .These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

Basis the above, SRL classifies a candidate's Fitness Status into one of the following categories:

- Fit (As per requested panel of tests) SRL Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the
- specific test panel requested for.
 Fit (with medical advice) (As per requested panel of tests) This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician's
- consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job.

 Fitness on Hold (Temporary Unfit) (As per requested panel of tests) Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly
- Unfit (As per requested panel of tests) An unfit report by SRL Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs.



Scan to View Report

Page 17 Of 18





CLIENT CODE: C000138382
CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030

NEW DELHI 1: DELHI INDIA 8800465156 SRL Ltd

7/3, SRINARAYANI ARCADE 1ST FLOOR, ABOVE BATA SHOWROOM

BROOKEFIELD MAIN ROAD, KUNDALAHALLI

BANGALORE, 560037 KARNATAKA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956 Email : wellness.itpl@srl.in

PATIENT NAME: K V MOHANDASS

PATIENT ID: KVMOM09068075

ACCESSION NO: 0075WB00182 AGE: 42 Years SEX: Male ABHA NO:

DRAWN: 25/02/2023 08:09 RECEIVED: 25/02/2023 08:11 REPORTED: 27/02/2023 17:11

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Units

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ULTRASOUND ABDOMEN
ULTRASOUND ABDOMEN
GRADE 1 FATTY LIVER

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

Dr. Anamika Pal Lab Head

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062





Scan to View Report